Summary
5.16 -0.03(-0.58%)03/13/2026
Compass Therapeutics, Inc. (CMPX)
CMPX reported last earnings on 2025-11-05 after the market. An EPS of $-0.08 was observed compared to an estimated EPS of $-0.14, resulting in a surprise value of $0.06. A revenue of $0 million was observed compared to an estimated revenue of $0 million, resulting in a surprise value of $0 Million.
Compass Therapeutics, Inc. (CMPX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years |
| -0.58 | 2.24 | 21.90 | 65.89 | 137.44 | 234.00 | -41.06 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan!
Fundamental Ratings
| Category | Rating |
| Main Rating | C |
| Recommended Rating | Sell |
| DCF | Neutral |
| ROE | Strong Sell |
| ROA | Strong Sell |
| Debt/Equity | Neutral |
| P/E | Strong Sell |
| P/B | Sell |
Earnings
| Trading Data | ||
| Close | 5.16 | |
| Open | 5.27 | |
| High | 5.34 | |
| Low | 5.08 | |
| Volume | 749,168 | |
| Change | -0.03 | |
| Change % | -0.58 | |
| Avg Volume (20 Days) | 2,046,891 | |
| Volume/Avg Volume (20 Days) Ratio | 0.37 | |
| 52 Week Range | 1.34 - 5.16 | |
| Price vs 52 Week High | 0.00% | |
| Price vs 52 Week Low | 285.07% | |
| Range | 0.00 | |
| Gap Up/Down | -0.17 | |
Profitibility | ||
| Market Capitalization (Mln) | 581 | |
| Revenue per share | 0.0000 | |
| Net Income per share | -0.3597 | |
| Dividend Yield | 0.0000 | |
| Dividend Share | 0.00% | |
Valuations | ||
| Enterprise Value | 0.00% | |
| PE Ratio | -14.4286 | |
| PB Ratio | 0.0000 | |
| PTB Ratio | 0.0000 | |
Liquidity | ||
| Debt/Equity Ratio | 0.0000 | |
| Net Debt/EBIDTA Ratio | 0.0000 | |
| Current Ratio | 0.0000 | |
Enterprise Value and Cash Flow | ||
| EV/Sales Ratio | 0.0000 | |
| EV/EBIDTA Ratio | 0.0000 | |
| EV/Free Cash Flow Ratio | 0.0000 | |
03/05 07:30 EST - globenewswire.com
Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update
In the Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer, the prespecified event threshold of 80% overall survival (OS) events was reached in Q1 2026; as a result, the analyses of progression-free survival (PFS) and OS are expected...
Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update
In the Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer, the prespecified event threshold of 80% overall survival (OS) events was reached in Q1 2026; as a result, the analyses of progression-free survival (PFS) and OS are expected...
03/02 12:29 EST - fool.com
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing
Purchased 2,532,419 shares in CMPX; position value was $13,599,090 as of December 31, 2025 Quarter-end value of the CMPX stake was $13,599,090, resulting from the new position initiated during the quarter Transaction represented a 1.89% change relative to the fund's reported 13F AUM Post-trade...
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing
Purchased 2,532,419 shares in CMPX; position value was $13,599,090 as of December 31, 2025 Quarter-end value of the CMPX stake was $13,599,090, resulting from the new position initiated during the quarter Transaction represented a 1.89% change relative to the fund's reported 13F AUM Post-trade...
02/17 10:40 EST - zacks.com
Is Compass Therapeutics, Inc. (CMPX) Outperforming Other Medical Stocks This Year?
Here is how Compass Therapeutics, Inc. (CMPX) and Ekso Bionics (EKSO) have performed compared to their sector so far this year.
Is Compass Therapeutics, Inc. (CMPX) Outperforming Other Medical Stocks This Year?
Here is how Compass Therapeutics, Inc. (CMPX) and Ekso Bionics (EKSO) have performed compared to their sector so far this year.
01/27 10:56 EST - zacks.com
Wall Street Analysts See an 113.73% Upside in Compass Therapeutics, Inc. (CMPX): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 113.7% in Compass Therapeutics, Inc. (CMPX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the...
Wall Street Analysts See an 113.73% Upside in Compass Therapeutics, Inc. (CMPX): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 113.7% in Compass Therapeutics, Inc. (CMPX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the...
01/20 11:25 EST - seekingalpha.com
Compass Therapeutics: Exciting Clinical Updates Inbound For 2026
Compass Therapeutics remains a 'Buy,' but valuation above $1B stretches risk/reward as it awaits pivotal clinical catalysts. Tovecimig's early data in biliary tract and refractory colorectal cancers show promise, with key COMPANION-002 updates expected late Q1 2026. CMPX's cash runway extends into...
Compass Therapeutics: Exciting Clinical Updates Inbound For 2026
Compass Therapeutics remains a 'Buy,' but valuation above $1B stretches risk/reward as it awaits pivotal clinical catalysts. Tovecimig's early data in biliary tract and refractory colorectal cancers show promise, with key COMPANION-002 updates expected late Q1 2026. CMPX's cash runway extends into...
01/14 13:26 EST - seekingalpha.com
Compass Therapeutics, Inc. (CMPX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Compass Therapeutics, Inc. (CMPX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Compass Therapeutics, Inc. (CMPX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Compass Therapeutics, Inc. (CMPX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
01/06 08:00 EST - globenewswire.com
Compass Therapeutics Provides Corporate Update
The analyses of progression-free survival (PFS) and overall survival (OS) remain on track for late Q1 2026 in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC). In the ongoing Phase 1 dose-escalation study...
Compass Therapeutics Provides Corporate Update
The analyses of progression-free survival (PFS) and overall survival (OS) remain on track for late Q1 2026 in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC). In the ongoing Phase 1 dose-escalation study...
01/05 16:30 EST - globenewswire.com
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced it granted stock options to two new employees under...
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced it granted stock options to two new employees under...
01/05 08:00 EST - globenewswire.com
Compass Therapeutics Announces Key Leadership Appointments
BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the appointments of Arjun Prasad, MBA, MPH as Chief...
Compass Therapeutics Announces Key Leadership Appointments
BOSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the appointments of Arjun Prasad, MBA, MPH as Chief...
12/31 01:32 EST - defenseworld.net
Compass Therapeutics (NASDAQ:CMPX) Shares Up 4.5% – What’s Next?
Compass Therapeutics, Inc. (NASDAQ: CMPX - Get Free Report) shares rose 4.5% during mid-day trading on Tuesday. The stock traded as high as $5.39 and last traded at $5.38. Approximately 1,662,732 shares were traded during mid-day trading, a decline of 2% from the average daily volume of 1,705,218...
Compass Therapeutics (NASDAQ:CMPX) Shares Up 4.5% – What’s Next?
Compass Therapeutics, Inc. (NASDAQ: CMPX - Get Free Report) shares rose 4.5% during mid-day trading on Tuesday. The stock traded as high as $5.39 and last traded at $5.38. Approximately 1,662,732 shares were traded during mid-day trading, a decline of 2% from the average daily volume of 1,705,218...
12/19 10:41 EST - zacks.com
Are Medical Stocks Lagging Compass Therapeutics, Inc. (CMPX) This Year?
Here is how Compass Therapeutics, Inc. (CMPX) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Compass Therapeutics, Inc. (CMPX) This Year?
Here is how Compass Therapeutics, Inc. (CMPX) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
12/17 07:30 EST - globenewswire.com
Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference
BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will present at the J.P. Morgan 2026 Healthcare Conference on...
Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference
BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will present at the J.P. Morgan 2026 Healthcare Conference on...
12/12 10:56 EST - zacks.com
Wall Street Analysts Think Compass Therapeutics, Inc. (CMPX) Could Surge 134.14%: Read This Before Placing a Bet
The consensus price target hints at a 134.1% upside potential for Compass Therapeutics, Inc. (CMPX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Think Compass Therapeutics, Inc. (CMPX) Could Surge 134.14%: Read This Before Placing a Bet
The consensus price target hints at a 134.1% upside potential for Compass Therapeutics, Inc. (CMPX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
12/08 13:00 EST - zacks.com
Here's Why Compass Therapeutics, Inc. (CMPX) is a Great Momentum Stock to Buy
Does Compass Therapeutics, Inc. (CMPX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here's Why Compass Therapeutics, Inc. (CMPX) is a Great Momentum Stock to Buy
Does Compass Therapeutics, Inc. (CMPX) have what it takes to be a top stock pick for momentum investors? Let's find out.
12/08 01:10 EST - defenseworld.net
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Moderate Buy” from Analysts
Compass Therapeutics, Inc. (NASDAQ: CMPX - Get Free Report) has received a consensus rating of "Moderate Buy" from the fifteen analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, thirteen have given a buy recommendation...
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Moderate Buy” from Analysts
Compass Therapeutics, Inc. (NASDAQ: CMPX - Get Free Report) has received a consensus rating of "Moderate Buy" from the fifteen analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, thirteen have given a buy recommendation...
12/04 17:08 EST - seekingalpha.com
Compass Therapeutics, Inc. (CMPX) Presents at Evercore 8th Annual Healthcare Conference Transcript
Compass Therapeutics, Inc. (CMPX) Presents at Evercore 8th Annual Healthcare Conference Transcript
Compass Therapeutics, Inc. (CMPX) Presents at Evercore 8th Annual Healthcare Conference Transcript
Compass Therapeutics, Inc. (CMPX) Presents at Evercore 8th Annual Healthcare Conference Transcript
12/04 16:48 EST - seekingalpha.com
Compass Therapeutics, Inc. (CMPX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Compass Therapeutics, Inc. (CMPX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Compass Therapeutics, Inc. (CMPX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Compass Therapeutics, Inc. (CMPX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
12/03 08:15 EST - 247wallst.com
Here Are Wednesday’s Top Wall Street Analyst Upgrades and Downgrades: American Eagle Outfitters, Equinix, Garmin, Honeywell, Uber, Wendy’s and More
Pre-Market Stock Futures: The futures are trading higher on Wednesday after a stellar day across Wall Street on Tuesday. All of the major indices finished the day higher, with the technology-heavy NASDAQ leading the way, closing up 0.59% at 23,413. The S&P 500 ended the session at 6,829, up 0.25%...
Here Are Wednesday’s Top Wall Street Analyst Upgrades and Downgrades: American Eagle Outfitters, Equinix, Garmin, Honeywell, Uber, Wendy’s and More
Pre-Market Stock Futures: The futures are trading higher on Wednesday after a stellar day across Wall Street on Tuesday. All of the major indices finished the day higher, with the technology-heavy NASDAQ leading the way, closing up 0.59% at 23,413. The S&P 500 ended the session at 6,829, up 0.25%...
11/26 10:56 EST - zacks.com
Wall Street Analysts Believe Compass Therapeutics, Inc. (CMPX) Could Rally 154.09%: Here's is How to Trade
The mean of analysts' price targets for Compass Therapeutics, Inc. (CMPX) points to a 154.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Believe Compass Therapeutics, Inc. (CMPX) Could Rally 154.09%: Here's is How to Trade
The mean of analysts' price targets for Compass Therapeutics, Inc. (CMPX) points to a 154.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
11/25 08:00 EST - globenewswire.com
Compass Therapeutics to Participate in Upcoming December Investor Events
BOSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in the following investor events during the month...
Compass Therapeutics to Participate in Upcoming December Investor Events
BOSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in the following investor events during the month...
Market News
×
Loading news…